Inventaire - your friends and communities are your best library

Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study

автор

Patrick Rossignol

1969 -

опубликовано в: American Journal of Nephrology

дата публикации: 2018

язык: английский язык

главная тема: нефрология, Хроническая болезнь почек

Cites articles 35

Дата

Заголовок

Авторы

2017-12-07

Spironolactone and resistant hypertension in heart failure with preserved ejection fraction.
2016-12-04

Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality

Marie Evans, Johan Ärnlöv, Bengt Lindholm, Josef Coresh
2016-04-01

Resistant Hypertension and Chronic Kidney Disease: a Dangerous Liaison
2016-04-01

New Evidence Supporting the Use of Mineralocorticoid Receptor Blockers in Drug-Resistant Hypertension
2015-11-26

A Randomized Trial of Intensive versus Standard Blood-Pressure Control

Cora E Lewis, Mahboob Rahman, Michael V. Rocco, Kaycee M Sink, Suzanne Oparil
2015-09-18

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

Isla S. Mackenzie, Sandosh Padmanabhan, Mark Caulfield, Томас Макдональд
2015-07-27

Thresholds for Diagnosing Hypertension Based on Automated Office Blood Pressure Measurements and Cardiovascular Risk.

Lisa Dolovich
2015-05-15

Clinical efficacy of spironolactone for resistant hypertension: a meta analysis from randomized controlled clinical trials
2015-05-22

The renal effects of mineralocorticoid receptor antagonists

Stefano Bianchi
2015-03-23

The Effects of Aldosterone Antagonists in Patients With Resistant Hypertension: A Meta-Analysis of Randomized and Nonrandomized Studies
2014-04-29

Aldosterone antagonists for preventing the progression of chronic kidney disease

Suetonia Palmer, Davide Bolignano, Giovanni Strippoli, Sankar Navaneethan
2014-03

Reduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and/or diabetic patients. A meta-regression analysis of 32 randomized trials

Martin F Reiner, Alessandra Dei Cas, Gianluigi Savarese, Bruno Trimarco
2014-02-05

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

Cheryl Dennison Himmelfarb
2013-12-17

Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension

Aletta E. Schutte, Rhian Touyz, Stephen Harrap, John Chalmers, Debbie L Cohen
2013-10-01

2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension

Krzysztof Narkiewicz
2013-07-18

Prevalence of apparent treatment-resistant hypertension among individuals with CKD.

Marguerite R Irvin, Paul Muntner, David G Warnock, Rikki M Tanner, Daniel T. Lackland, Emmy K Bell, Orlando M Gutiérrez, C Barrett Bowling, Suzanne Oparil
2013-07-01

2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Renata Cífková, Maurizio Galderisi, Tiny Jaarsma, Sverre E. Kjeldsen, Roland E. Schmieder, Paulus Kirchhof, Anna Dominiczak, Luis Miguel Ruilope, Alberto Zanchetti, Krzysztof Narkiewicz, Faiez Zannad, Guy De Backer, Giuseppe Mancia, Per Anton Sirnes, Diederick Grobbee
2012-12-10

Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism.

Felix Beuschlein, Katharina Lang, Marcus Quinkler
2011-06-30

Changes in albuminuria predict mortality and morbidity in patients with vascular disease

Giuseppe Mancia, Salim Yusuf, Roland E. Schmieder
2011-04-09

Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)

Claire Gudex
2011-01-05

Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial

Faiez Zannad, Bertram Pitt, Stefan D. Anker, Dalane W Kitzman
2011-03-28

Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring

Julian Segura, Anna Oliveras, Luis Miguel Ruilope
2010-08-10

Salt, aldosterone, and insulin resistance: impact on the cardiovascular system
2009-09-09

Predictors of hyperkalemia risk following hypertension control with aldosterone blockade
2008-06-01

Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research

David C Goff
2007-09-01

The incidence and implications of aldosterone breakthrough
2007-02-19

Effect of spironolactone on blood pressure in subjects with resistant hypertension
2006-10-11

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease

Stefano Bianchi
2006-11-01

Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function
2004-07-01

Aldosterone in the development and progression of renal injury
2004-05-01

K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease
2003-11-01

Efficacy of low-dose spironolactone in subjects with resistant hypertension

Статья - wd:Q58765834

Добро пожаловать в Inventaire

the library of your friends and communities

узнать больше